Evidence map›Paper›PMID 37212982›Full record

GuidelineInternational journal of clinical oncology2023

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.

Yoichi Naito, Saori Mishima, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama and 22 more

Open access · hybridAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 1 country.

Yoichi NaitoNational Cancer Center Hospital East, Kashiwa, Japan.
Saori MishimaNational Cancer Center Hospital East, Kashiwa, Japan.ORCID http://orcid.org/0000-0002-5922-1487
Kiwamu AkagiSaitama Cancer Center, Saitama, Japan.
Naomi HayashiThe Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Akira HirasawaOkayama University, Okayama, Japan.
Tomoro HishikiChiba University, Chiba, Japan.
Ataru IgarashiYokohama City University School of Medicine, Yokohama, Japan.
Masafumi IkedaNational Cancer Center Hospital East, Kashiwa, Japan.
Shigenori KadowakiAichi Cancer Center, Aichi, Japan.
Hiroaki KajiyamaNagoya University, Aichi, Japan.
Motohiro KatoThe University of Tokyo, Tokyo, Japan.
Hirotsugu KenmotsuShizuoka Cancer Center, Shizuoka, Japan.
Yasuhiro KoderaNagoya University Hospital, Aichi, Japan.
Keigo KomineTohoku University, Miyagi, Japan.
Takafumi KoyamaNational Cancer Center Hospital, Tokyo, Japan.
Osamu MaedaNagoya University Hospital, Aichi, Japan.
Mitsuru MiyachiKyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroshi NishiharaKeio University, Tokyo, Japan.
Hiroyuki NishiyamaTsukuba University, Ibaraki, Japan.
Shouichi OhgaKyushu University, Fukuoka, Japan.
Wataru OkamotoHiroshima University Hospital, Hiroshima, Japan.
Eiji OkiKyushu University, Fukuoka, Japan.
Shigeru OnoJichi Medical University, Tochigi, Japan.
Masashi SanadaNational Hospital Organization Nagoya Medical Center, Aichi, Japan.
Ikuo SekineTsukuba University, Ibaraki, Japan.
Tadao TakanoTohoku University, Miyagi, Japan.
Kayoko TaoNational Cancer Center Hospital, Tokyo, Japan.
Keita TerashimaNational Center for Child Health and Development, Tokyo, Japan.
Katsuya TsuchiharaNational Cancer Center Hospital East, Kashiwa, Japan.
Yasushi YatabeNational Cancer Center Hospital, Tokyo, Japan.
Takayuki YoshinoNational Cancer Center Hospital East, Kashiwa, Japan.
Eishi BabaDepartment of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. baba.eishi.889@m.kyushu-u.ac.jp.
National Cancer Center Hospital East · JPKyushu University · JPTokyo National Hospital · JPNagoya University Hospital · JPTohoku University · JPAichi Cancer Center · JPChiba University · JPHiroshima University Hospital · JPJichi Medical University · JPKeio University · JPKyoto Prefectural University of Medicine · JPNagoya University · JPNational Center For Child Health and Development · JPNational Hospital Organization · JPOkayama University · JPSaitama Cancer Center · JPShizuoka Cancer Center · JPThe Cancer Institute Hospital · JPThe University of Tokyo · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical trials have reported the efficacy of tropomyosin receptor kinase (TRK) inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors. The accumulated evidence of tumor-agnostic agent has made since TRK inhibitors were approved and used in clinical practice. Therefore, we have revised the 'Japan Society of Clinical Oncology (JSCO)/Japanese Society of Medical Oncology (JSMO)-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese Society of Pediatric Hematology/Oncology (JSPHO)'.

methodsClinical questions regarding medical care were formulated for patients with NTRK fusion-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by JSCO, JSMO, and JSPHO voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done.

resultsThe current guideline describes 3 clinical questions and 14 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors.

conclusionThe committee proposed 14 recommendations for performing NTRK testing properly to select patients who are likely to benefit from TRK inhibitors.

Indexed as

NeoplasmsReceptor Protein-Tyrosine KinasesTropomyosinAdultChildEast Asian PeopleGene FusionHumansJapanProtein Kinase InhibitorsReceptor, trkANTRK1 protein, humanProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesReceptor, trkATropomyosinAdvanced solid tumorClinical practice guidelineNeurotrophic receptor tyrosine kinase (NTRK) fusionTropomyosin receptor kinase (TRK) inhibitorTumor-agnostic treatment

Identifiers

PMID37212982
PMCPMC10310565
OpenAlexW4377220302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.